Latest Interviews

OUTLOOK THERAPEUTICS

"If our ophthalmic bevacizumab is approved, we will potentially enhance the standard of care for patients with disorders like wet AMD, diabetic macular edema, and branch retinal vein occlusion by removing concerns related to off-label repackaged IV product."

LESCHACO

"Though a major change in the design and organization of global supply chains does not happen overnight, we do see a lot more caution in the medium-to-long-term planning."

INFINEUM

"A combination of unprecedented shipping costs coupled with steeply rising raw material costs and challenges around securing raw materials has had the entire additives industry struggling to pass on their costs."

INTEGRA PETROCHEMICALS

“One of our guiding principles is to be simultaneously global and local (glocal), which gives our clients a double advantage: A diversified portfolio and geographically optimum supplies from the cheapest markets,and an intimate understanding of local markets so as to gain the best arbitrage.”

QUOTIENT SCIENCES

"The focus of our integrated Translational Pharmaceutics programs is to provide the customer with a development platform capable of responding in real-time to emerging development data and maintain an overall timeline to proof of concept."

"Our fixed-price, fastest DNA-to-IND program is packaged in a standardized platform to allow clients to bring a new antibody molecule to IND filing in a rapid amount of time."